Affiliation:
1. Shanxi Medical University Taiyuan Shanxi China
2. Department of Dermatology First Hospital of Shanxi Medical University Taiyuan Shanxi China
3. Department of Dermatology Taiyuan Central Hospital of Shanxi Medical University Taiyuan Shanxi China
Abstract
AbstractThe effectiveness and safety of biological agents for treating psoriasis have been confirmed; however, their effects on glucose metabolism biomarkers in psoriasis patients remain unclear. A systematic review and meta‐analysis were performed according to PRISMA guidelines. The final analysis enrolled 12 studies, including eight randomized controlled trial (RCT) (n = 5628 patients) and four observational cohort studies (OBSs) (n = 393 patients). The meta‐analysis comprising nine studies (six RCTs and three OBSs) revealed a slight reduction in the levels of HOMA‐IR associated with the use of biological therapies in OBS (biological therapies vs. traditional therapies: WMD = −0.2, CI = −0.10 to 0.50, p = 0.02). Although a considerable number of studies were analysed, our review did not show a significant alteration in HOMA‐IR levels among patients treated with biological therapies such as IL‐17 inhibitors and IL‐12/23 inhibitors at weeks 12–16 in RCTs. We also did not observe remarkable alterations in the fasting plasma glucose levels of patients in both OBS and RCT. Additional RCT on a larger scale and duration is required to provide more conclusive evidence regarding the effect of biological agents on glycogen metabolism in psoriasis.